NASDAQ:NTRA - Nasdaq - US6323071042 - Common Stock - Currency: USD
153.79
-0.69 (-0.45%)
The current stock price of NTRA is 153.79 USD. In the past month the price increased by 3.7%. In the past year, price increased by 67.78%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 329.14B | ||
AMGN | AMGEN INC | 14.17 | 150.99B | ||
GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
BIIB | BIOGEN INC | 7.22 | 17.39B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B | ||
UTHR | UNITED THERAPEUTICS CORP | 11.84 | 13.09B |
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 4,424 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
NATERA INC
13011 Mccallen Pass, Building A Suite 100
Austin TEXAS 78753 US
CEO: Steve Chapman
Employees: 3288
Company Website: https://www.natera.com/
Investor Relations: https://investor.natera.com
Phone: 16502499090
The current stock price of NTRA is 153.79 USD. The price decreased by -0.45% in the last trading session.
The exchange symbol of NATERA INC is NTRA and it is listed on the Nasdaq exchange.
NTRA stock is listed on the Nasdaq exchange.
27 analysts have analysed NTRA and the average price target is 199.97 USD. This implies a price increase of 30.03% is expected in the next year compared to the current price of 153.79. Check the NATERA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NATERA INC (NTRA) has a market capitalization of 20.79B USD. This makes NTRA a Large Cap stock.
NATERA INC (NTRA) currently has 3288 employees.
NATERA INC (NTRA) has a support level at 151.31 and a resistance level at 153.8. Check the full technical report for a detailed analysis of NTRA support and resistance levels.
The Revenue of NATERA INC (NTRA) is expected to grow by 15.92% in the next year. Check the estimates tab for more information on the NTRA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NTRA does not pay a dividend.
NATERA INC (NTRA) will report earnings on 2025-05-07, after the market close.
NATERA INC (NTRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
The outstanding short interest for NATERA INC (NTRA) is 4.29% of its float. Check the ownership tab for more information on the NTRA short interest.
ChartMill assigns a technical rating of 7 / 10 to NTRA. When comparing the yearly performance of all stocks, NTRA is one of the better performing stocks in the market, outperforming 94.01% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to NTRA. While NTRA has a great health rating, there are worries on its profitability.
Over the last trailing twelve months NTRA reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 59.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -11.47% | ||
ROE | -15.93% | ||
Debt/Equity | 0.07 |
ChartMill assigns a Buy % Consensus number of 87% to NTRA. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -43.9% and a revenue growth 15.92% for NTRA